G1 Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 100
- Market Cap
- $376.1M
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05874401
- Locations
- 🇧🇪
CHU de Liège, Liege, Belgium
🇧🇪Centre Hospitalier de l'Ardenne, Libramont, Belgium
🇵🇱Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05113966
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
- Conditions
- Breast CancerTriple Negative Breast Cancer
- Interventions
- Drug: CylophosphamideBiological: Pembrolizumab (Investigator discretion)
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05112536
- Locations
- 🇺🇸
UCLA Department of Medicine - Hematology/Oncology, Santa Monica, California, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
- Conditions
- Myelosuppression AdultBladder CancerUrothelial CarcinomaChemotherapy-induced NeutropeniaMetastatic Bladder Cancer
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT04887831
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Beacon Cancer Center PLLC, Coeur d'Alene, Idaho, United States
🇫🇷Institut Bergonié - Oncologie Médicale et Pédiatrique, Bordeaux cedex, Gironde, France
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
- Conditions
- NSCLCMetastatic Non-Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04863248
- Locations
- 🇺🇸
Regional Cancer Car Associates, LLC, Little Silver, New Jersey, United States
🇺🇸Summit Medical Group, Florham Park, New Jersey, United States
🇺🇸Ironwood Cancer & Research Centers, Phoenix, Arizona, United States
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
- Conditions
- TNBC - Triple-Negative Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT04799249
- Locations
- 🇺🇸
Banner M.D. Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Florida Cancer Specialists - North (SCRI), Saint Petersburg, Florida, United States
🇺🇸Maryland Oncology Hematology, P.A., Clinton, Maryland, United States
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
- Conditions
- Colorectal Cancer MetastaticMyelosuppression-AdultChemotherapeutic Toxicity
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 326
- Registration Number
- NCT04607668
- Locations
- 🇺🇸
AZ Oncology Associates - HOPE, Tucson, Arizona, United States
🇺🇸Keck Medical Center of USC Pasadena, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
- Conditions
- Myelosuppression AdultChemotherapeutic ToxicitySmall Cell Lung Cancer
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- G1 Therapeutics, Inc.
- Registration Number
- NCT04504513
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03455829
- Locations
- 🇺🇸
St Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
- Conditions
- Carcinoma, Ductal, BreastMetastatic Breast CancerStage IV Breast CancerBreast Cancer FemaleBreast NeoplasmBreast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT03455270
- Locations
- 🇺🇦
Spizhenko Clinic, Kiev, Ukraine
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪UZ Leuven, Leuven, Belgium